Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
34 hedge funds and large institutions have $24M invested in Vyant Bio, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 7 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
6% more funds holding
Funds holding: 32 → 34 (+2)
28% less capital invested
Capital invested by funds: $33.3M → $24M (-$9.34M)
63% less call options, than puts
Call options by funds: $59K | Put options by funds: $158K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$3.42M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2.55M |
| 3 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
+$384K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$360K |
| 5 |
PP
PDT Partners
New York
|
+$337K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Timpani Capital Management
Milwaukee,
Wisconsin
|
-$2.97M |
| 2 |
CM
Castleark Management
Chicago,
Illinois
|
-$2.81M |
| 3 |
DM
Deerfield Management
New York
|
-$1.38M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.37M |
| 5 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$1.16M |
VYNT Hedge Fund Activity: Q2 2014 in Review
34 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q2 2014, worth a combined $24M — down 28% from $33.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VYNT positions and 7 closed out — a net gain of 2 holders — while 11 added to existing stakes and 5 trimmed.
The largest buyer was Northpointe Capital, opening a new position worth an estimated $3.42M. The largest seller was Timpani Capital Management, exiting entirely with an estimated $2.97M sold.
- 34 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q2 2014, up from 32 in Q1 2014.
- Funds reported $24M of Vyant Bio, Inc. Common Stock stock for Q2 2014, down 28% quarter-over-quarter.
- 9 funds opened new Vyant Bio, Inc. Common Stock positions in Q2 2014 and 7 closed out, a net change of +2 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q2 2014 was Northpointe Capital, an estimated $3.42M added.
- The largest Vyant Bio, Inc. Common Stock seller in Q2 2014 was Timpani Capital Management, an estimated $2.97M sold.
Based on aggregated 13F filings for Q2 2014.